Pharmafile Logo

It’s time to measure outcomes

Lucid launch their new metrics platform

- PMLiVE

With shrinking budgets and shorter timelines, pharmaceutical companies are keen to invest their assets smartly in medical education programmes that will guarantee their desired outcomes. Medical communications have aimed to keep pace with this development through evaluation forms and post-event surveys. However, these usually measure the level of audience satisfaction, rather than our actual progress towards our ultimate goal. In the latest issue of PME, Dennis O’Brien (Lucid Co-founder and CEO) discusses the need to demonstrate that medical education programmes are truly achieving what they promise.

“It’s time to think of new ways of measuring effectiveness, particularly relating to outcomes,” says Dennis. He comments on the frequent use of patient information leaflets: “If we haven’t got evidence that it improves patient outcomes, then we shouldn’t be doing it. Let’s invest our time where it matters.”

Dennis explains Lucid’s new solution to this challenge of measuring outcomes: “Our latest methodology at Lucid is a metrics platform. It provides a strategic approach to education that starts by defining our WHY – the outcomes we want to achieve. We then look at what behaviours we need in our audience to get us there. Where once we thought it was only our medicines that could improve outcomes, we can now demonstrate that it’s our services and our communications that make a difference.”

To read Dennis’ full article, click the following link: http://www.pmlive.com/__data/assets/pdf_file/0004/1199893/45_Lucid_TL.pdf

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrate big wins at PMEA 2015

Success for Lucid at PMEA 2015

Lucid invests in their Futures programme with a new hire

Lucid Group continues their expansion

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Making a difference to patients with IBD

Changing lives with medical education

Lucid Group showcases new KOL identification and mapping tool

Advancing Expert identification with digital new tool from Lucid Group

Lucid CEO discusses his inspiration and passion for changing patients’ lives

Changing patients' lives with innovative methodologies in medical education

Lucid Group starts new trend for CME in IBD education

A tailored educational event in IBD